Le Lézard
Classified in: Health, Business
Subject: VEN

NuVera Medical Raises New Financing


CAMPBELL, Calif., Feb. 6, 2019 /PRNewswire/ -- NuVera Medical Inc., a portfolio company of Shifamed LLC, announced today it completed the first closing of a $15 million financing round led by Cormorant Asset Management with continued participation from the Capital Partnership, Lilly Asia Ventures, and other existing shareholders.

NuVera Medical is a privately-held company focused on enabling a new era in transcatheter cardiac interventions through the advancement of real-time 3D intracardiac echocardiography (4D ICE). Therapeutic advances in both the electrophysiology (EP) ablation market and the rapidly evolving structural heart (SH) market present new challenges in procedural guidance underserved by current methods of imaging. The NuVera platform represents a true paradigm shift in real-time 3D guidance, enabling the expansion and sustainable market adoption of a growing body of interventional procedures performed in the chambers of the heart. 

"We are pleased to expand our relationship with NuVera Medical and Shifamed," said Cormorant Asset Management CEO, Bihua Chen. "We are confident in the NuVera team's ability to execute and deliver this important procedural advancement to the cardiology market."

"The results of our preclinical work to date have been very positive," said Todor Jeliaskov, CEO of NuVera Medical. "With these results, we believe that the value proposition of the NuVera technology in electrophysiology and structural heart applications is further demonstrated, and we look forward to advancing the product to the next stage of development."

In the United States, 2D ICE is currently used in approximately 85% of EP ablation cases, representing a $250M market in the US alone at a CAGR of 17%. By offering the benefits of side-by-side 2D and 4D intracardiac images with a single ICE catheter, the NuVera system is poised for swift adoption within the rapidly growing and evolving EP market.

In addition, real-time 4D imaging will continue to play a critical and enabling role in the adoption of the increasingly complex procedures that are expanding the SH market. Currently, operators rely on 4D TEE for real-time 3D visualization, which requires a dedicated sonographer and is typically done under general anesthesia, adding significant cost and time to the procedure along with an increased length of stay. Providing 4D imaging on an ICE platform offers the potential to reduce the hospital's cost burden and puts control of the imaging catheter into the hands of the interventionalist.

About NuVera Medical Inc.

NuVera Medical is a privately held medical device company formed by Shifamed LLC, a Silicon Valley based medical innovation hub. To learn more about NuVera Medical, please visit www.nuveramedical.com.

About Shifamed LLC

Founded by serial entrepreneur Amr Salahieh, Shifamed LLC is a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com.

MEDIA CONTACT:
Katie Arnold
SPRIG Consulting LLC
+1 (408) 805-0520
[email protected]

 

SOURCE NuVera Medical Inc.


These press releases may also interest you

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...



News published on and distributed by: